<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03646968</url>
  </required_header>
  <id_info>
    <org_study_id>SAVE</org_study_id>
    <nct_id>NCT03646968</nct_id>
  </id_info>
  <brief_title>Study of Anlotinib Combined With Docetaxel in Non-Driver Mutation Non-squamous NSCLC: the Save Study</brief_title>
  <acronym>SAVE</acronym>
  <official_title>Phase II Study to Evaluate the Effectiveness and Safety of Anlotinib Combined With Docetaxel in Progress After First Line Standard Cheomotherapy in Advanced Non-driver Mutation Non- Squamous Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yongchang Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined
      with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver
      mutation non- squamous non-small cell lung cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the Effectiveness and Safety of Anlotinib combined
      with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver
      mutation non- squamous non-small cell lung cancer .According to the result of TAX317,the ORR
      of second line standard chemotherapy was 5- 8%. We expect the ORR was 20%. Using PASS11, we
      calculated the sample size of this study was 39 , according to 10% censoring,the expected
      sample size is 43.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2018</start_date>
  <completion_date type="Anticipated">June 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>may 2018- may 2019 (1 year)</time_frame>
    <description>overall response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>may 2018- may 2019 (1 year)</time_frame>
    <description>Progression survival time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>may 2018- may 2019 (1 year)</time_frame>
    <description>overall survival time</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Non-Squamous Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Cohorts</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase II Study to evaluate the Effectiveness and Safety of Anlotinib combined with Docetaxel in Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib and Docetaxel</intervention_name>
    <description>Patients who was Progress after First line Standard Cheomotherapy in advanced non-driver mutation non- squamous non-small cell lung cancer recieved the treatment of Anlotinib and Docetaxel (Anlotinib, 12mg, po,qd and Docetaxel 175mg/m2, ivgtt, every 21day)</description>
    <arm_group_label>Cohorts</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18，Pathologically proven Non squamous non small cell lung cancer

               -  No-drive gene mutaion (EGFR、ALK、ROS1） by NGS

               -  Progress after second line

               -  PS score 0-2

        Exclusion Criteria:

          -  Patients received second line treatment

          -  Patients received treatment of Anlotinib or Docetaxel

          -  Patients with contraindication of chemotherapy

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yongchang Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hunan Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yongchang Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>7+861383123436</phone_ext>
    <email>yangnong0217@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yongchang Zhang, MD</last_name>
    <phone>+8613873123436</phone>
    <phone_ext>+8613873123436</phone_ext>
    <email>zhangyongchang@csu.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hunan Cancer Hospital</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762323</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yongchang Zhang, MD</last_name>
      <phone>+86 731 89762321</phone>
      <email>zhangyongchang@csu.edu.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Nong Yang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 23, 2018</study_first_submitted>
  <study_first_submitted_qc>August 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2018</study_first_posted>
  <last_update_submitted>March 24, 2020</last_update_submitted>
  <last_update_submitted_qc>March 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 26, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Yongchang Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Anlotinib Combined With Docetaxel</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

